ClinicalTrials.gg
RecruitingNCT06824467Updated Nov 17, 2026

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

A Phase 3 interventional study of Sacituzumab tirumotecan and Bevacizumab in Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer, sponsored by Merck Sharp & Dohme LLC. Recruiting at 203 sites in 29 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Nov 17, 202610 sites added3 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
770
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Ovarian Neoplasms by Merck & Co., Inc — 6 open to participants now, 7 under way, 5 of them phase 3. Ovarian Neoplasms · Merck & Co., Inc.

Planned enrollment
4th of 25
770 · median 132
Started
2025
with 1 other
Phase 3
6 of 27
4 open now
Registered
22nd of 27
by date

Among the 27 studies in Ovarian Neoplasms by Merck & Co., Inc, this one is the 4th largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2025, is one of 6 in phase 3, and was the 22nd registered.

Ovarian Neoplasms

3,389 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

6 of the 27 studies in Ovarian Neoplasms by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 601 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Ovarian Neoplasms by Merck & Co., Inc, or all of them as a file.
02

Study summary

The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.

03

Conditions studied

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has locally advanced or , confirmed epithelial ovarian, primary peritoneal, or fallopian tube carcinoma of certain histologies
  • Has received 4 or more cycles of platinum-based doublet chemotherapy in and a total of 6 to 8 cycles of carboplatin-based doublet chemotherapy in second-line setting for ovarian cancer (OC)
  • Has platinum-sensitive epithelial OC
  • Has provided tissue of a tumor lesion that was not previously irradiated
  • (HIV)-infected participants must have well controlled HIV on antiretroviral therapy
  • Participants who are surface antigen positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to allocation (Part 1) or randomization (Part 2)
  • Participants with a history of virus (HCV) infection are eligible if HCV viral load is undetectable at screening
  • Has an performance status of 0 or 1 assessed within 7 days before allocation (Part 1) or randomization (Part 2)

Exclusion criteria

Exclusion Criteria:

  • Has nonepithelial cancers (germ cell tumors and sex cord-stromal tumors), low-grade serous tumors, low-grade endometrioid tumors, borderline tumors (low malignant potential), mucinous, seromucinous that is predominantly mucinous, malignant Brenner's tumor and undifferentiated carcinoma
  • Has platinum-resistant OC or platinum- OC
  • Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
  • Has active inflammatory bowel disease requiring medication or previous history of inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis, or chronic diarrhea)
  • Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
  • Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required , has current pneumonitis/ILD, or has suspected pneumonitis or ILD that cannot be ruled out by standard diagnostic assessments at Screening
  • -infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Has received more than 2 for OC
  • Has received prior systemic anticancer therapy within 3 weeks or 5 half-lives (whichever is shorter) before allocation (Part 1) or randomization (Part 2)
  • Has received prior radiotherapy within 2 weeks of allocation (Part 1) or randomization (Part 2), or has radiation related toxicities, requiring corticosteroids
  • Has an additional that is progressing or has required active treatment within the past 3 years
  • Has active central nervous system (CNS) and/or carcinomatous meningitis
  • Has an active infection requiring systemic therapy
  • Has active or ongoing stomatitis
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
770 participants (estimated)

Study arms

  • Experimental
    Part 1: Sacituzumab tirumotecan + Bevacizumab

    Participants receive 4 mg/kg of sacituzumab tirumotecan once every 2 weeks (Q2W) plus 15 mg/kg of bevacizumab once every 3 weeks (Q3W) via intravenous (IV) infusion over 6 weeks

    Biological: Sacituzumab tirumotecan · Biological: Bevacizumab · Drug: H1 receptor antagonist · Drug: H2 receptor antagonist · Drug: Acetaminophen (or equivalent) · Drug: Dexamethasone (or equivalent) · Drug: Steroid mouthwash (dexamethasone or equivalent)

  • Experimental
    Part 2: Sacituzumab tirumotecan

    Participants receive 4 mg/kg of sacituzumab tirumotecan Q2W via IV infusion for up to approximately 2 years or until progressive disease or discontinuation. At the physician's discretion, participants receive 15 mg/kg of bevacizumab Q3W via IV infusion until progressive disease or discontinuation.

    Biological: Sacituzumab tirumotecan · Biological: Bevacizumab · Drug: H1 receptor antagonist · Drug: H2 receptor antagonist · Drug: Acetaminophen (or equivalent) · Drug: Dexamethasone (or equivalent) · Drug: Steroid mouthwash (dexamethasone or equivalent)

  • Active comparator
    Part 2: Standard of care (SOC)

    Participants receive local standard of care until progressive disease or discontinuation. At the physician's discretion, participants receive 15 mg/kg of bevacizumab Q3W via IV infusion until progressive disease or discontinuation.

    Biological: Bevacizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to 6 weeks

  2. Part 1: Number of Participants Who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to 6 weeks

  3. Part 2: Progression-Free Survival (PFS)

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death from any cause, whichever occurs first. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented.

    Time frame: Up to approximately 4 years

Secondary outcomes

  1. Part 2: Overall Survival (OS)

    OS is defined as the time from randomization to death due to any cause.

    Time frame: Up to approximately 6 years

  2. Part 2: Number of Participants With One or More AEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 4 years

  3. Part 2: Number of Participants Who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 4 years

  4. Part 2: Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status-Quality of Life Score

    The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients. Participant responses to Item 30 (""How would you rate your overall quality of life during the past week?") is scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher value indicates a better level of function. The change from baseline in EORTC QLQ-C30 Item 30 score will be reported.

    Time frame: Baseline and up to approximately 4 years

  5. Part 2: Change From Baseline in EORTC QLQ-C30 Physical Functioning Score

    The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better level of physical functioning.

    Time frame: Baseline and up to approximately 4 years

  6. Part 2: Change From Baseline in EORTC QLQ-C30 Role Functioning Score

    The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "Were you limited in doing either your work or other daily activities during the past week?" and " Were you limited in pursuing your hobbies or other leisure time activities during the past week?" will be scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. Higher scores indicate a more impaired level of role functioning. Change from baseline in the role functioning score will be presented.

    Time frame: Baseline and up to approximately 4 years

  7. Part 2: Change From Baseline in EORTC Quality of Life Questionnaire-Ovarian Cancer Module 28 (QLQ-OV28) abdominal/gastrointestinal (GI) symptom scale

    The EORTC QLQ-OV28 is an OC-specific, and psychometrically and clinically validated module to supplement the EORTC QLQ-C30. The EORTC QLQ-OV28 abdominal/GI symptom scale is scored on a 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much).

    Time frame: Baseline and up to approximately 4 years

07

Study locations

202 of 203 sites recruiting
  • University of Alabama at Birmingham ( Site 0006)
    Birmingham, Alabama 35249, United States
    Recruiting
    • Study Coordinator · Contact(205) 934-7442
  • Alaska Women's Cancer Care ( Site 0096)
    Anchorage, Alaska 99508, United States
    Recruiting
    • Study Coordinator · Contact907-562-4673
  • City of Hope Comprehensive Cancer Center ( Site 0007)
    Duarte, California 91010, United States
    Recruiting
    • Study Coordinator · Contact626-256-4673
  • City of Hope Lennar Foundation Cancer Center ( Site 0024)
    Irvine, California 92618, United States
    Recruiting
    • Study Coordinator · Contact626-256-4673
  • Hoag Memorial Hospital Presbyterian ( Site 0019)
    Newport Beach, California 92663, United States
    Recruiting
    • Study Coordinator · Contact949-764-4577
  • UCSF Medical Center at Mission Bay ( Site 0013)
    San Francisco, California 94158, United States
    Recruiting
    • Study Coordinator · Contact415-353-3000
  • John Muir Health Cancer Center ( Site 0016)
    Walnut Creek, California 94598, United States
    Recruiting
    • Study Coordinator · Contact925-692-5603
  • Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0001)
    New Haven, Connecticut 06510, United States
    Recruiting
    • Study Coordinator · Contact203-785-5702
  • Mount Sinai Braman Comprehensive Cancer Center ( Site 0078)
    Miami Beach, Florida 33140, United States
    Recruiting
    • Study Coordinator · Contact305-674-2625
  • Sarasota Memorial Hospital ( Site 0075)
    Sarasota, Florida 34239, United States
    Recruiting
    • Study Coordinator · Contact941-917-2225
  • Florida Cancer Specialists East ( Site 7000)
    West Palm Beach, Florida 33401, United States
    Recruiting
    • Study Coordinator · Contact561-366-4100
  • Winship Cancer Institute of Emory University ( Site 0086)
    Atlanta, Georgia 30322, United States
    Recruiting
    • Study Coordinator · Contact404-778-1900
  • Augusta University - Georgia Cancer Center ( Site 0066)
    Augusta, Georgia 30912, United States
    Recruiting
    • Study Coordinator · Contact706-721-6744
  • Parkview Research Center at Parkview Regional Medical Center ( Site 0003)
    Fort Wayne, Indiana 46845, United States
    Recruiting
    • Study Coordinator · Contact260-425-6981
  • The University of Kansas Cancer Center - Westwood ( Site 0002)
    Westwood, Kansas 66205, United States
    Recruiting
    • Study Coordinator · Contact913-588-6215
  • Women's Cancer Care ( Site 0067)
    Covington, Louisiana 70433, United States
    Recruiting
    • Study Coordinator · Contact985-892-2252
  • Maine Medical Center Research Institute-MaineHealth/Maine Medical Partners - GynOnc ( Site 0008)
    Scarborough, Maine 04074, United States
    Recruiting
    • Study Coordinator · Contact207-883-0069
  • Minnesota Oncology Hematology (MNO) ( Site 8002)
    Maplewood, Minnesota 55109, United States
    Recruiting
    • Study Coordinator · Contact615-693-2574
  • St. Dominic's Hospital ( Site 0064)
    Jackson, Mississippi 39216, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Washington University School of Medicine ( Site 0052)
    St Louis, Missouri 63110, United States
    Recruiting
    • Study Coordinator · Contact314-454-6215
  • Nebraska Methodist Hospital ( Site 0053)
    Omaha, Nebraska 68114, United States
    Recruiting
    • Study Coordinator · Contact402-354-8534
  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0081)
    Hackensack, New Jersey 07601, United States
    Recruiting
    • Study Coordinator · Contact551-996-5855
  • Rutgers Cancer Institute of New Jersey ( Site 0071)
    New Brunswick, New Jersey 08901, United States
    Recruiting
    • Study Coordinator · Contact732-235-7258
  • University of New Mexico Comprehensive Cancer Center ( Site 0055)
    Albuquerque, New Mexico 87131, United States
    Recruiting
    • Study Coordinator · Contact505-272-4946
  • NYU Langone Hospital - Long Island ( Site 0015)
    Mineola, New York 11501, United States
    Recruiting
    • Study Coordinator · Contact516-663-0333
  • Laura and Isaac Perlmutter Cancer Center ( Site 0076)
    New York, New York 10016, United States
    Recruiting
    • Study Coordinator · Contact212-731-6000
  • FirstHealth Cancer Center ( Site 0079)
    Pinehurst, North Carolina 28374, United States
    Recruiting
    • Study Coordinator · Contact910-715-8684
  • University of Cincinnati Medical Center ( Site 0090)
    Cincinnati, Ohio 45219, United States
    Recruiting
    • Study Coordinator · Contact513-584-1958
  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0054)
    Columbus, Ohio 43210, United States
    Recruiting
    • Study Coordinator · Contact614-293-3300
  • Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0056)
    Tulsa, Oklahoma 74146, United States
    Recruiting
    • Study Coordinator · Contact918-505-3200
  • Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8010)
    Eugene, Oregon 97401, United States
    Recruiting
    • Study Coordinator · Contact541-683-5001
  • Allegheny Health Network West Penn Hospital ( Site 0099)
    Pittsburgh, Pennsylvania 15224, United States
    Recruiting
    • Study Coordinator · Contact412-578-5000
  • Women & Infants Hospital ( Site 0050)
    Providence, Rhode Island 02905, United States
    Recruiting
    • Study Coordinator · Contact401-274-1100
  • Henry-Joyce Cancer Clinic ( Site 0060)
    Nashville, Tennessee 37232, United States
    Recruiting
    • Study Coordinator · Contact615-936-8422
  • Texas Oncology - Central/South Texas ( Site 8009)
    Austin, Texas 78758, United States
    Recruiting
    • Study Coordinator · Contact512-873-8900
  • Texas Oncology - DFW ( Site 8001)
    Fort Worth, Texas 76104, United States
    Recruiting
    • Study Coordinator · Contact817-413-1500
  • University Of Texas Health Science Center -San Antonio ( Site 0095)
    San Antonio, Texas 78229, United States
    Recruiting
    • Study Coordinator · Contact210-567-7000
  • Texas Oncology - San Antonio ( Site 8005)
    San Antonio, Texas 78240, United States
    Recruiting
    • Study Coordinator · Contact210-595-5300
  • Texas Oncology - Gulf Coast ( Site 8003)
    Webster, Texas 77598, United States
    Recruiting
    • Study Coordinator · Contact281-332-7505
  • Virginia Cancer Specialists (VCS) ( Site 8011)
    Fairfax, Virginia 22031, United States
    Recruiting
    • Study Coordinator · Contact(571) 350-8400
  • Froedtert and Medical College of Wisconsin ( Site 0073)
    Milwaukee, Wisconsin 53226, United States
    Recruiting
    • Study Coordinator · Contact262-805-6634
  • Instituto Alexander Fleming ( Site 2909)
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1426ANZ, Argentina
    Recruiting
    • Study Coordinator · Contact5411 3221 8900
  • Instituto de Investigaciones Clinicas Mar del Plata ( Site 2901)
    Mar del Plata, Buenos Aires B7600FZO, Argentina
    Recruiting
    • Study Coordinator · Contact+54 223 496 3224
  • Fundación Respirar ( Site 2912)
    Buenos Aires, Buenos Aires F.D. C1426AAL, Argentina
    Recruiting
    • Study Coordinator · Contact+5491167281601
  • Instituto de Oncologia de Rosario ( Site 2910)
    Rosario, Santa Fe Province S2000KZE, Argentina
    Recruiting
    • Study Coordinator · Contact+543414218909
  • Hospital Aleman ( Site 2903)
    CABA, C1118AAT, Argentina
    Recruiting
    • Study Coordinator · Contact+541148277000
  • Hospital Italiano de Cordoba ( Site 2908)
    Córdoba, 5000, Argentina
    Recruiting
    • Study Coordinator · Contact+543517078224
  • Blacktown Hospital ( Site 0211)
    Sydney, New South Wales 2148, Australia
    Recruiting
    • Study Coordinator · Contact+61286705071
  • Gallipoli Medical Research Ltd ( Site 0214)
    Brisbane, Queensland 4120, Australia
    Recruiting
    • Study Coordinator · Contact+61733947284
  • Epworth Freemasons ( Site 0217)
    East Melbourne, Victoria 3002, Australia
    Recruiting
    • Study Coordinator · Contact+61385595000
  • Frankston Hospital ( Site 0216)
    Frankston, Victoria 3199, Australia
    Recruiting
    • Study Coordinator · Contact+61409848084
  • Medizinische Universitat Wien ( Site 0102)
    Vienna, State of Vienna 1090, Austria
    Recruiting
    • Study Coordinator · Contact004314040061030
  • Medizinische Universität Graz-Abteilung für Gynäkologie / Onkologie ( Site 0104)
    Graz, Styria 8036, Austria
    Recruiting
    • Study Coordinator · Contact004331638581081
  • Medizinische Universitaet Innsbruck-Univ.-Klinik f. Gynäkologie und Geburtshilfe ( Site 0101)
    Innsbruck, Tyrol 6020, Austria
    Recruiting
    • Study Coordinator · Contact004351250482403
  • Antwerp University Hospital ( Site 0304)
    Edegem, Antwerpen 2650, Belgium
    Recruiting
    • Study Coordinator · Contact+ 32 3 821 47 19
  • Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman ( Site 0306)
    Liège, Liege 4000, Belgium
    Recruiting
    • Study Coordinator · Contact+32 4 323 5332
  • AZ Sint-Lucas ( Site 0305)
    Ghent, Oost-Vlaanderen 9000, Belgium
    Recruiting
    • Study Coordinator · Contact+32 9 224 66 20
  • UZ Leuven ( Site 0301)
    Leuven, Vlaams-Brabant 3000, Belgium
    Recruiting
    • Study Coordinator · Contact+32 16 34 74 19
  • CHU UCL Namur/Site Sainte Elisabeth ( Site 0302)
    Namur, 5000, Belgium
    Recruiting
    • Study Coordinator · Contact+32 (0)81 70 28 44
  • Liga Norte Riograndense Contra o Cancer ( Site 0423)
    Natal, Rio Grande do Norte 59062-000, Brazil
    Recruiting
    • Study Coordinator · Contact+558440095600
  • Hospital São Lucas da PUCRS ( Site 0425)
    Porto Alegre, Rio Grande do Sul 90610000, Brazil
    Recruiting
    • Study Coordinator · Contact+555133203000
  • ANIMI - Unidade de Tratamento Oncologico ( Site 0419)
    Lages, Santa Catarina 88501-001, Brazil
    Recruiting
    • Study Coordinator · Contact+554933805200
  • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto ( Site 0413)
    São José do Rio Preto, São Paulo 15090-000, Brazil
    Recruiting
    • Study Coordinator · Contact+55 17 32015054
  • Instituto Nacional de Câncer - INCA ( Site 0422)
    Rio de Janeiro, 20220-410, Brazil
    Recruiting
    • Study Coordinator · Contact+552132072985
  • Hospital Paulistano ( Site 0421)
    São Paulo, 01321-001, Brazil
    Recruiting
    • Study Coordinator · Contact+551130161000
  • IBCC - Núcleo de Pesquisa e Ensino ( Site 0424)
    São Paulo, 04014-002, Brazil
    Recruiting
    • Study Coordinator · Contact+551134744264
  • Arthur J.E. Child Comprehensive Cancer Centre ( Site 0512)
    Calgary, Alberta T2N 5G2, Canada
    Recruiting
    • Study Coordinator · Contact5872315594
  • Health Sciences North Research Institute ( Site 0517)
    Greater Sudbury, Ontario P3E 5J1, Canada
    Recruiting
    • Study Coordinator · Contact7055237100
  • Trillium Health Partners - Credit Valley Hospital ( Site 0508)
    Mississauga, Ontario L5M 2N1, Canada
    Recruiting
    • Study Coordinator · Contact905-813-2200
  • Princess Margaret Cancer Centre ( Site 0518)
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
    • Study Coordinator · Contact(416) 946-4501
  • CIUSSS de l'Est-de-l'Île-de-Montréal ( Site 0505)
    Montreal, Quebec H1T 2M4, Canada
    Recruiting
    • Study Coordinator · Contact514-252-3400
  • McGill University Health Centre ( Site 0502)
    Montreal, Quebec H4A 3J1, Canada
    Recruiting
    • Study Coordinator · Contact514-934-1934
  • Clinica Puerto Montt ( Site 0615)
    Port Montt, Los Lagos Region 5507642, Chile
    Recruiting
    • Study Coordinator · Contact56961687093
  • Fundación Arturo López Pérez ( Site 0616)
    Santiago, Region M. de Santiago 7500921, Chile
    Recruiting
    • Study Coordinator · Contact56224205098
  • Pontificia Universidad Catolica de Chile ( Site 0611)
    Santiago, Region M. de Santiago 8330032, Chile
    Recruiting
    • Study Coordinator · Contact56934331806
  • Bradfordhill-Clinical Area ( Site 0610)
    Santiago, Region M. de Santiago 8420383, Chile
    Recruiting
    • Study Coordinator · Contact56229490970
  • ONCOCENTRO APYS-ACEREY ( Site 0612)
    Viña del Mar, Valparaiso 2520598, Chile
    Recruiting
    • Study Coordinator · Contact+56323320860
  • FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0806)
    Bogotá, Bogota D.C. 110131, Colombia
    Recruiting
    • Study Coordinator · Contact+576015948650
  • Instituto Nacional De Cancerologia ( Site 0807)
    Bogotá, Bogota D.C. 111511, Colombia
    Recruiting
    • Study Coordinator · Contact+573154208007
  • Oncologos Del Occidente ( Site 0805)
    Pereira, Risaralda Department 660001, Colombia
    Recruiting
    • Study Coordinator · Contact+57 3187715522
  • Fakultni Nemocnice Brno Bohunice ( Site 3324)
    Brno, Brno-mesto 602 00, Czechia
    Recruiting
    • Study Coordinator · Contact420532233843
  • Fakultni nemocnice Ostrava ( Site 3323)
    Ostrava-Poruba, Ostrava Mesto 708 52, Czechia
    Recruiting
    • Study Coordinator · Contact+420597371804
  • Vseobecna fakultni nemocnice v Praze ( Site 3325)
    Prague, 128 08, Czechia
    Recruiting
    • Study Coordinator · Contact+420224967451
  • Fakultní nemocnice Motol a Homolka ( Site 3322)
    Prague, 150 06, Czechia
    Recruiting
    • Study Coordinator · Contact+420224434749
  • Rigshospitalet ( Site 0904)
    Copenhagen, Capital Region 2100, Denmark
    Recruiting
    • Study Coordinator · Contact+45 35453545
  • Herlev Hospital ( Site 0903)
    Herlev, Capital Region 2730, Denmark
    Recruiting
    • Study Coordinator · Contact+45 38683868
  • Aalborg Universitetshospital ( Site 0901)
    Aalborg, North Denmark 9000, Denmark
    Recruiting
    • Study Coordinator · Contact97661400
  • Vejle Sygehus ( Site 0902)
    Vejle, Region Syddanmark 7100, Denmark
    Recruiting
    • Study Coordinator · Contact79406088
  • Oulun yliopistollinen sairaala ( Site 1003)
    Oulu, North Ostrobothnia 90220, Finland
    Recruiting
    • Study Coordinator · Contact+358505794505
  • Kuopion Yliopistollinen Sairaala ( Site 1004)
    Kuopio, Northern Savonia 70200, Finland
    Recruiting
    • Study Coordinator · Contact+358447174617
  • Tampereen yliopistollinen sairaala ( Site 1002)
    Tampere, Pirkanmaa 33520, Finland
    Recruiting
    • Study Coordinator · Contact+358407274241
  • Centre Oscar Lambret ( Site 1104)
    Lille, Ain 59020, France
    Recruiting
    • Study Coordinator · Contact+33320295959
  • Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest ( Site 1101)
    Bordeaux, Aquitaine 33076, France
    Recruiting
    • Study Coordinator · Contact+33556333333
  • Centre Hopitalier Lyon Sud ( Site 1110)
    Pierre-Bénite, Auvergne-Rhône-Alpes 69310, France
    Recruiting
    • Study Coordinator · Contact+33478864318
  • Centre Francois Baclesse ( Site 1108)
    Caen, Calvados 14076, France
    Recruiting
    • Study Coordinator · Contact+33231459700
  • Hôpital Privé Des Côtes d'Armor ( Site 1106)
    Plérin, Cotes-d Armor 22190, France
    Recruiting
    • Study Coordinator · Contact+33257240243
  • LBM ONCOPOLE CLAUDIUS REGAUD ( Site 1109)
    Toulouse, Haute-Garonne 31059, France
    Recruiting
    • Study Coordinator · Contact+33531155101
  • Pôle Santé Léonard de Vinci ( Site 1112)
    Chambray-lès-Tours, Indre-et-Loire 37170, France
    Recruiting
    • Study Coordinator · Contact+33247602060
  • Groupe Hospitalier Broca Cochin Hotel Dieu ( Site 1111)
    Paris, Paris 75014, France
    Recruiting
    • Study Coordinator · Contact+33158411439
  • Institut De Cancerologie De L Ouest ( Site 1107)
    Saint-Herblain, Pays de la Loire Region 44805, France
    Recruiting
    • Study Coordinator · Contact+33 2 40 67 99 00

Showing the first 100 of 203 sites across 29 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Apr 2029, 48 months after the start.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's planned 48 months is close to that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2025
First posted
Feb 13, 2025
StartActual
Apr 9, 2025
Primary completionEst.
Apr 27, 2029
CompletionEst.
Nov 9, 2032
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
10 sites added, 3 sites removed
Show 10 added (5 United States, 2 Ireland, 1 Chile, 1 Czechia, 1 France)
  • The University of Kansas Cancer Center - Westwood ( Site 0002) · Westwood, United States
  • Fundación Arturo López Pérez ( Site 0616) · Santiago, Chile
  • City of Hope Lennar Foundation Cancer Center ( Site 0024) · Irvine, United States
  • City of Hope Comprehensive Cancer Center ( Site 0007) · Duarte, United States
  • Froedtert and Medical College of Wisconsin ( Site 0073) · Milwaukee, United States
  • Fakultní nemocnice Motol a Homolka ( Site 3322) · Prague, Czechia
  • Gustave Roussy ( Site 1103) · Villejuif, France
  • St. James's Hospital ( Site 1301) · Dublin, Ireland
  • St Vincent s Hospital ( Site 1302) · Dublin, Ireland
  • Hoag Memorial Hospital Presbyterian ( Site 0019) · Newport Beach, United States
Show 3 removed
  • FALP ( Site 0616) · Santiago, Chile
  • Fakultni nemocnice v Motole ( Site 3322) · Prague, Czechia
  • St James Hospital ( Site 1301) · Dublin, Ireland
across 4 updates, Oct 6, 2026 – Nov 17, 2026
Show all 4 updates
  1. Nov 17, 2026
    1 site added
    Show site
    • Hoag Memorial Hospital Presbyterian ( Site 0019) · Newport Beach, United States
  2. Nov 10, 2026
    6 sites added, 2 sites removed
    Show 6 added (2 United States, 2 Ireland, 1 Czechia, 1 France)
    • City of Hope Comprehensive Cancer Center ( Site 0007) · Duarte, United States
    • Froedtert and Medical College of Wisconsin ( Site 0073) · Milwaukee, United States
    • Fakultní nemocnice Motol a Homolka ( Site 3322) · Prague, Czechia
    • Gustave Roussy ( Site 1103) · Villejuif, France
    • St. James's Hospital ( Site 1301) · Dublin, Ireland
    • St Vincent s Hospital ( Site 1302) · Dublin, Ireland
    Show 2 removed
    • Fakultni nemocnice v Motole ( Site 3322) · Prague, Czechia
    • St James Hospital ( Site 1301) · Dublin, Ireland
    + 1 other change: verification date
  3. Oct 13, 2026
    1 site added
    Show site
    • City of Hope Lennar Foundation Cancer Center ( Site 0024) · Irvine, United States
  4. Oct 6, 2026
    2 sites added, 1 site removed
    Show 2 added (1 United States, 1 Chile)
    • The University of Kansas Cancer Center - Westwood ( Site 0002) · Westwood, United States
    • Fundación Arturo López Pérez ( Site 0616) · Santiago, Chile
    Show 1 removed
    • FALP ( Site 0616) · Santiago, Chile
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06824467
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Responsible party
Sponsor
First posted
Feb 13, 2025
Start date
Apr 9, 2025
Primary completion
Apr 27, 2029 (estimated)
Completion
Nov 9, 2032 (estimated)
Last update
Nov 17, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sacituzumab tirumotecan

Start the discussion